Tego Science Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
6,307
6,738
7,492
8,343
8,642
Cost of Goods Sold (COGS) incl. D&A
1,381
1,393
1,537
1,647
1,833
Gross Income
4,927
5,345
5,955
6,696
6,810
SG&A Expense
3,107
3,629
4,573
4,331
4,750
EBIT
1,820
1,705
1,368
2,334
2,033
Unusual Expense
49
-
24
1,710
8,539
Non Operating Income/Expense
56
11
47
39
2
Interest Expense
114
130
-
151
526
Pretax Income
1,961
1,792
1,566
644
6,609
Income Tax
365
258
51
144
336
Equity in Affiliates
-
-
41
35
-
Consolidated Net Income
1,596
1,534
1,473
754
6,273
Net Income
1,596
1,534
1,473
772
6,246
Net Income After Extraordinaries
1,596
1,534
1,473
772
6,246
Net Income Available to Common
1,596
1,534
1,473
772
6,246
EPS (Basic)
265.03
246.00
199.00
104.00
836.00
Basic Shares Outstanding
6
6
7
7
7
EPS (Diluted)
265.03
245.91
198.95
104.21
836.24
Diluted Shares Outstanding
6
6
7
7
7
EBITDA
2,067
1,989
1,670
2,592
2,264
Other Operating Expense
-
11
13
31
26
Non-Operating Interest Income
264
228
220
211
424
Minority Interest Expense
-
-
-
18
27

About Tego Science

View Profile
Address
Unit 101 & 102, 1/F
Seoul SL 08505
Korea, Republic Of
Employees -
Website http://www.tegoscience.com
Updated 09/14/2018
Tego Science, Inc. engages in the manufacture and sale of cell therapy products. Its products include Holoderm, Kaloderm, Neoderm, and skin bank and contract research services. The company was founded by Jeon Sae-Wha and Jeon Jae-Wook on March 20, 2001 and is headquartered in Seoul, South Korea.